27463942|t|Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial
27463942|a|In the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2 dose - reduction criteria-80 years or older, weight 60 kg or less, and creatinine level 1.5 mg/dL or higher-received a reduced dose of apixaban of 2.5 mg twice daily. Little is known about patients with 1 dose - reduction criterion who received the 5 mg twice daily dose of apixaban. To determine the frequency of 1 dose - reduction criterion and whether the effects of the 5 mg twice daily dose of apixaban on stroke or systemic embolism and bleeding varied among patients with 1 or no dose - reduction criteria. Among 18 201 patients in the ARISTOTLE trial, 17 322 were included in this analysis. Annualized event rates of stroke or systemic embolism and major bleeding and hazard ratios (HRs) and 95% CIs were evaluated. Interactions between the effects of apixaban vs warfarin and the presence of 1 or no dose - reduction criteria were assessed. The first patient was enrolled in the ARISTOTLE trial on December 19, 2006, and follow-up was completed on January 30, 2011. Data were analyzed from January 2015 to May 30, 2016. Analysis of major bleeding included events during study drug treatment. Analysis of stroke or systemic embolism was based on intention to treat. Of the patients with 1 or no dose - reduction criteria assigned to receive the 5 mg twice daily dose of apixaban or warfarin, 3966 had 1 dose - reduction criterion; these patients had higher rates of stroke or systemic embolism (HR, 1.47; 95% CI, 1.20-1.81) and major bleeding (HR, 1.89; 95% CI, 1.62-2.20) compared with those with no dose - reduction criteria (n = 13 356). The benefit of the 5 mg twice daily dose of apixaban (n = 8665) compared with warfarin (n = 8657) on stroke or systemic embolism in patients with 1 dose - reduction criterion (HR, 0.94; 95% CI, 0.66-1.32) and no dose - reduction criterion (HR, 0.77; 95% CI, 0.62-0.97) were similar (P for interaction = .36). Similarly, the benefit of 5 mg twice daily dose of apixaban compared with warfarin on major bleeding in patients with 1 dose - reduction criterion (HR, 0.68; 95% CI, 0.53-0.87) and no dose - reduction criterion (HR, 0.72; 95% CI, 0.60-0.86) were similar (P for interaction = .71). Similar patterns were seen for each dose - reduction criterion and across the spectrum of age, body weight, creatinine level, and creatinine clearance. Patients with atrial fibrillation and isolated advanced age, low body weight, or renal dysfunction have a higher risk of stroke or systemic embolism and major bleeding but show consistent benefits with the 5 mg twice daily dose of apixaban vs warfarin compared with patients without these characteristics. The 5 mg twice daily dose of apixaban is safe, efficacious, and appropriate for patients with only 1 dose - reduction criterion. clinicaltrials.gov Identifier: NCT00412984.
27463942	0	8	Apixaban	T109,T121	C1831808
27463942	14	19	Twice	T081	C1948050
27463942	20	25	Daily	T079	C0332173
27463942	30	38	Clinical	T080	C0205210
27463942	39	47	Outcomes	T169	C1274040
27463942	51	59	Patients	T101	C0030705
27463942	65	84	Atrial Fibrillation	T047	C0004238
27463942	89	97	Advanced	T080	C0205179
27463942	98	101	Age	T032	C0001779
27463942	103	106	Low	T080	C0205251
27463942	107	118	Body Weight	T032	C0005910
27463942	123	127	High	T080	C0205250
27463942	128	138	Creatinine	T109,T123	C0010294
27463942	142	160	Secondary Analysis	UnknownType	C0683944
27463942	166	191	Randomized Clinical Trial	T062,T170	C0206034
27463942	199	207	Apixaban	T109,T121	C1831808
27463942	212	221	Reduction	T080	C0392756
27463942	225	231	Stroke	T047	C0038454
27463942	242	270	Thromboembolic Complications	T046	C0040038
27463942	274	293	Atrial Fibrillation	T047	C0004238
27463942	295	304	ARISTOTLE	T062	C0008976
27463942	306	311	trial	T062	C0008976
27463942	326	330	dose	T081	C0178602
27463942	334	342	apixaban	T109,T121	C1831808
27463942	352	357	twice	T081	C1948050
27463942	358	363	daily	T079	C0332173
27463942	365	373	patients	T101	C0030705
27463942	390	394	dose	T081	C0178602
27463942	397	406	reduction	T080	C0392756
27463942	419	424	years	T079	C0439234
27463942	435	441	weight	T032	C0005910
27463942	461	477	creatinine level	T033	C0428279
27463942	472	477	level	T080	C0441889
27463942	509	516	reduced	T080	C0392756
27463942	517	521	dose	T081	C0178602
27463942	525	533	apixaban	T109,T121	C1831808
27463942	544	549	twice	T081	C1948050
27463942	550	555	daily	T079	C0332173
27463942	579	587	patients	T101	C0030705
27463942	595	599	dose	T081	C0178602
27463942	602	611	reduction	T080	C0392756
27463942	644	649	twice	T081	C1948050
27463942	650	655	daily	T079	C0332173
27463942	656	660	dose	T081	C0178602
27463942	664	672	apixaban	T109,T121	C1831808
27463942	691	700	frequency	T079	C0439603
27463942	706	710	dose	T081	C0178602
27463942	713	722	reduction	T080	C0392756
27463942	749	759	effects of	T080	C1704420
27463942	769	774	twice	T081	C1948050
27463942	775	780	daily	T079	C0332173
27463942	781	785	dose	T081	C0178602
27463942	789	797	apixaban	T109,T121	C1831808
27463942	801	807	stroke	T047	C0038454
27463942	811	828	systemic embolism	UnknownType	C0149876
27463942	833	841	bleeding	T046	C0019080
27463942	855	863	patients	T101	C0030705
27463942	877	881	dose	T081	C0178602
27463942	884	893	reduction	T080	C0392756
27463942	917	925	patients	T101	C0030705
27463942	933	948	ARISTOTLE trial	T062	C0008976
27463942	979	987	analysis	T062	C0936012
27463942	1015	1021	stroke	T047	C0038454
27463942	1025	1042	systemic embolism	UnknownType	C0149876
27463942	1053	1061	bleeding	T046	C0019080
27463942	1066	1079	hazard ratios	T081	C2985465
27463942	1081	1084	HRs	T081	C2985465
27463942	1094	1097	CIs	T081	C0009667
27463942	1103	1112	evaluated	T058	C0220825
27463942	1114	1126	Interactions	T169	C1704675
27463942	1139	1149	effects of	T080	C1704420
27463942	1150	1158	apixaban	T109,T121	C1831808
27463942	1162	1170	warfarin	T109,T121,T131	C0043031
27463942	1199	1203	dose	T081	C0178602
27463942	1206	1215	reduction	T080	C0392756
27463942	1230	1238	assessed	T052	C1516048
27463942	1250	1257	patient	T101	C0030705
27463942	1278	1293	ARISTOTLE trial	T062	C0008976
27463942	1320	1329	follow-up	T058	C1522577
27463942	1365	1369	Data	T078	C1511726
27463942	1419	1427	Analysis	T062	C0936012
27463942	1437	1445	bleeding	T046	C0019080
27463942	1469	1474	study	T062	C2603343
27463942	1475	1489	drug treatment	T061	C0013216
27463942	1491	1499	Analysis	T062	C0936012
27463942	1503	1509	stroke	T047	C0038454
27463942	1513	1530	systemic embolism	UnknownType	C0149876
27463942	1544	1553	intention	T080	C1283828
27463942	1557	1562	treat	T169	C1522326
27463942	1571	1579	patients	T101	C0030705
27463942	1593	1597	dose	T081	C0178602
27463942	1600	1609	reduction	T080	C0392756
27463942	1648	1653	twice	T081	C1948050
27463942	1654	1659	daily	T079	C0332173
27463942	1660	1664	dose	T081	C0178602
27463942	1668	1676	apixaban	T109,T121	C1831808
27463942	1680	1688	warfarin	T109,T121,T131	C0043031
27463942	1701	1705	dose	T081	C0178602
27463942	1708	1717	reduction	T080	C0392756
27463942	1735	1743	patients	T101	C0030705
27463942	1764	1770	stroke	T047	C0038454
27463942	1774	1791	systemic embolism	UnknownType	C0149876
27463942	1793	1795	HR	T081	C2985465
27463942	1807	1809	CI	T081	C0009667
27463942	1832	1840	bleeding	T046	C0019080
27463942	1842	1844	HR	T081	C2985465
27463942	1856	1858	CI	T081	C0009667
27463942	1899	1903	dose	T081	C0178602
27463942	1906	1915	reduction	T080	C0392756
27463942	1943	1950	benefit	T081	C0814225
27463942	1963	1968	twice	T081	C1948050
27463942	1969	1974	daily	T079	C0332173
27463942	1975	1979	dose	T081	C0178602
27463942	1983	1991	apixaban	T109,T121	C1831808
27463942	2017	2025	warfarin	T109,T121,T131	C0043031
27463942	2040	2046	stroke	T047	C0038454
27463942	2050	2067	systemic embolism	UnknownType	C0149876
27463942	2071	2079	patients	T101	C0030705
27463942	2087	2091	dose	T081	C0178602
27463942	2094	2103	reduction	T080	C0392756
27463942	2115	2117	HR	T081	C2985465
27463942	2129	2131	CI	T081	C0009667
27463942	2151	2155	dose	T081	C0178602
27463942	2158	2167	reduction	T080	C0392756
27463942	2179	2181	HR	T081	C2985465
27463942	2193	2195	CI	T081	C0009667
27463942	2263	2270	benefit	T081	C0814225
27463942	2279	2284	twice	T081	C1948050
27463942	2285	2290	daily	T079	C0332173
27463942	2291	2295	dose	T081	C0178602
27463942	2299	2307	apixaban	T109,T121	C1831808
27463942	2322	2330	warfarin	T109,T121,T131	C0043031
27463942	2340	2348	bleeding	T046	C0019080
27463942	2352	2360	patients	T101	C0030705
27463942	2368	2372	dose	T081	C0178602
27463942	2375	2384	reduction	T080	C0392756
27463942	2396	2398	HR	T081	C2985465
27463942	2410	2412	CI	T081	C0009667
27463942	2432	2436	dose	T081	C0178602
27463942	2439	2448	reduction	T080	C0392756
27463942	2460	2462	HR	T081	C2985465
27463942	2474	2476	CI	T081	C0009667
27463942	2565	2569	dose	T081	C0178602
27463942	2572	2581	reduction	T080	C0392756
27463942	2619	2622	age	T032	C0001779
27463942	2624	2635	body weight	T032	C0005910
27463942	2637	2653	creatinine level	T033	C0428279
27463942	2648	2653	level	T080	C0441889
27463942	2659	2669	creatinine	T109,T123	C0010294
27463942	2670	2679	clearance	T201	C1382187
27463942	2681	2689	Patients	T101	C0030705
27463942	2695	2714	atrial fibrillation	T047	C0004238
27463942	2737	2740	age	T032	C0001779
27463942	2746	2757	body weight	T032	C0005910
27463942	2762	2779	renal dysfunction	T033	C3279454
27463942	2794	2798	risk	T078	C0035647
27463942	2802	2808	stroke	T047	C0038454
27463942	2812	2829	systemic embolism	UnknownType	C0149876
27463942	2840	2848	bleeding	T046	C0019080
27463942	2869	2877	benefits	T081	C0814225
27463942	2892	2897	twice	T081	C1948050
27463942	2898	2903	daily	T079	C0332173
27463942	2904	2908	dose	T081	C0178602
27463942	2912	2920	apixaban	T109,T121	C1831808
27463942	2924	2932	warfarin	T109,T121,T131	C0043031
27463942	2947	2955	patients	T101	C0030705
27463942	2996	3001	twice	T081	C1948050
27463942	3002	3007	daily	T079	C0332173
27463942	3008	3012	dose	T081	C0178602
27463942	3016	3024	apixaban	T109,T121	C1831808
27463942	3067	3075	patients	T101	C0030705
27463942	3088	3092	dose	T081	C0178602
27463942	3095	3104	reduction	T080	C0392756